| Authors: |
Shimony S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Wang Y; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA., Cronin A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Walsh TP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Charles A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Slopen N; Department of Social and Behavioral Sciences, T.H. Chan Harvard School of Public Health, Boston, MA., Cho HL; Department of Medicine, Brigham and Women's Hospital, Boston, MA., Stahl M; Department of Medical Oncology and Hematology, Yale University School of Medicine and Yale Cancer Center, New Haven, CT., Bystrom RP; Department of Hematologic Malignancies and Cellular Therapy, Duke Blood Cancer Center, Durham, NC., Luskin MR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Abel GA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Center for Bioethics, Harvard Medical School, Boston, MA., DeAngelo DJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Stone RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Lindsley RC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Hantel A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Center for Bioethics, Harvard Medical School, Boston, MA. |
